Sanofi: FDA Grants Breakthrough Therapy Designation to Venglustat
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, an experimental oral glucosylceramide synthase inhibitor, for the treatment of neurological manifestations of type 3 Gaucher disease. This regulatory recognition follows the positive results from the phase 3 LEAP2MONO study.
Significant Clinical Improvements Lead to FDA Recognition
Venglustat received the FDA's Breakthrough Therapy designation based on data from the LEAP2MONO study, in which patients treated with venglustat showed statistically significant improvements in neurological symptoms compared to those receiving enzyme replacement therapy (imiglucerase). The drug works by reducing the abnormal accumulation of glucosphingolipids (GSL) and is designed to cross the blood-brain barrier to target the underlying pathology of the neurological effects. This regulatory step acknowledges the unmet medical need for individuals with type 3 Gaucher disease, particularly those with progressive neurological deterioration. Venglustat had previously received Fast Track and Orphan Drug designations for this indication in the United States, the European Union, and Japan.
Sanofi to Continue Global Regulatory Efforts for Venglustat by 2026
Sanofi will continue regulatory efforts globally for venglustat in the context of type 3 Gaucher disease by 2026. The LEAP2MONO study, conducted as a double-blind trial with an active comparator, included 43 adult and child patients aged 12 years and older. Venglustat was generally well tolerated, with no new safety signals identified compared to previous studies. An open-label phase of the study is ongoing, with results to be presented later.
